Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00666653 · ClinicalTrials.gov registry record · Phase 1

Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's Disease

A Phase 1 study of Parkinson's Disease, sponsored by Oregon Health and Science University.

Completed
Registry status
Phase 1
Development phase
13
Enrollment target
1
Study location

NCT00666653 is a Phase 1 study of Parkinson's Disease that has completed, run by Oregon Health and Science University. The registered enrollment target is 13 participants, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00666653, a Phase 1 study of Parkinson's Disease, has completed, sponsored by Oregon Health and Science University.

COMPLETED
Registry status
Phase 1
Development phase
13 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine whether there is a benefit to giving a dopamine agonist to a patient with Parkinson's disease who is already being treated with levodopa.

Conditions Studied

Interventions

  • DRUG pramipexole

Study Locations (1)

Oregon

  • Oregon Health & Science University - Portland

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2003-07
Est. Completion 2007-05
Phase Phase 1

What the Registry Record Tells You About NCT00666653

The ClinicalTrials.gov registry entry for NCT00666653 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (98% lower). The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which pramipexole is the first listed.

NCT00666653 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.

Frequently Asked Questions

What is clinical trial NCT00666653 about?

NCT00666653 is a clinical study titled "Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's Disease". The purpose of this study is to determine whether there is a benefit to giving a dopamine agonist to a patient with Parkinson's disease who is already being treated with levodopa.

What is the current status of trial NCT00666653?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2003-07. Estimated completion is 2007-05.

What conditions does trial NCT00666653 study?

This clinical trial studies the following conditions: Parkinson's Disease.

What interventions are being tested in trial NCT00666653?

The interventions under investigation include: pramipexole (DRUG).

Who is sponsoring clinical trial NCT00666653?

This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00666653 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Parkinson's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.